Exemestane: an alternative treatment option in early breast cancer

被引：0
|
作者：
Jassem, Jacek [1 ]
机构：
[1] Med Univ Gdansk, Dept Radiotherapy & Oncol, Gdansk, Poland
来源：
ANTI-CANCER DRUGS | 2008年 / 19卷
关键词：
D O I：
10.1097/01.cad.0000277607.85258.de
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S1 / S1
页数：1
相关论文
共 50 条
  • [41] Cryoablation: an Alternative in the Treatment of Breast Cancer
    Paucar Cepeda, Elvia
    Pinta Riofrio, Mario David
    Boada Zurita, Catalina del Rosario
    [J]. FINLAY, 2023, 13 (03):
  • [42] A randomized presurgical trial of alternative dosing of exemestane in postmenopausal women with early-stage ER-positive breast cancer.
    De Censi, Andrea
    Serrano, Davide
    Gandini, Sara
    Thomas, Parijatham S.
    Crew, Katherine D.
    Kumar, Nagi B.
    Lee, J. Jack
    Veronesi, Paolo
    Guerrieri-Gonzaga, Aliana
    Johansson, Harriet
    D'Amico, Mauro
    Guasone, Flavio
    Ertelsen, Bjorn-Erik
    Mellgren, Gunnar
    Bedrosian, Isabelle
    Dimond, Eileen
    Heckman-Stoddard, Brandy M.
    Szabo, Eva
    Brown, Powel
    Bonanni, Bernardo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [43] The effects on lipids of a 2-year adjuvant treatment with exemestane after tamoxifen in postmenopausal women with early breast cancer
    Gonnelli, S.
    Montagnani, A.
    Cadirni, A.
    Caffarelli, C.
    Montomoli, M.
    Campagna, M. S.
    Petrioli, R.
    Del Santo, K.
    Cuda, C.
    Nuti, R.
    [J]. ATHEROSCLEROSIS SUPPLEMENTS, 2006, 7 (03) : 409 - 409
  • [44] Estrogen-dependent breast cancer: The importance of androgen receptor in exemestane treatment
    Amaral, C.
    Augusto, T.
    Roleira, F.
    Tavares-Da-Silva, E.
    Correia-Da-Silva, G.
    Teixeira, N.
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [45] BRAWO - breast cancer treatment with Afinitor® (Everolimus) and exemestane for ER plus women
    Schuetz, F.
    Jackisch, C.
    Tesch, H.
    Bloch, W.
    Muth, M.
    Kreuzeder, J.
    Lueftner, D.
    [J]. ONKOLOGIE, 2013, 36 : 158 - 159
  • [46] Everolimus exposure and early metabolic response as predictors for treatment outcomes in breast cancer patients treated with everolimus and exemestane.
    Willemsen, Annelieke
    de Geus-Oei, Lioe-Fee
    De Boer, Maaike
    Tol, Jolien
    Kamm, Yvonne
    De Jong, Paul C.
    Vos, Allert Henrik
    de Groot, Jan Willem
    Mulder, Sasja F.
    Aarntzen, Erik H. J. G.
    Gerritsen, Winald R.
    Van Herpen, Carla M. L.
    Van Erp, Nielka P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [47] Letrozole is an effective option in the treatment of early-stage or advanced breast cancer in postmenopausal women
    不详
    [J]. Drugs & Therapy Perspectives, 2005, 21 (1) : 1 - 4
  • [48] Can exemestane improve adjuvant treatment for postmenopausal women with primary breast cancer?
    Lisa Hutchinson
    [J]. Nature Clinical Practice Oncology, 2004, 1 : 24 - 25
  • [49] Intraoperative radiation is not an alternative for early breast cancer
    Klein, Friederike
    [J]. GEBURTSHILFE UND FRAUENHEILKUNDE, 2024, 84 (02)
  • [50] Tislelizumab: an effective treatment option for early-stage triple-negative breast cancer
    Yu, Zhigang
    [J]. TRANSLATIONAL BREAST CANCER RESEARCH, 2024, 5
12345